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Abstract: Fabry disease is an X-linked, lysosomal storage disease caused by the inherited deficiency of the
enzyme α-galactosidase A. The diagnosis is usually late, with renal, cardiovascular and/or cerebral complica-
tions that reduce life expectancy. Angiokeratomas are asymptomatic lesions present as the initial manifestation
and usually less appreciated. Their detection is important for early diagnosis and institution of treatment with
enzyme replacement therapy, which prevents late complications reducing morbidity and mortality. We report a
case of a male teenager with acroparestesias and angiokeratomas. Family medical research discovered that his
mother and brother had similar signs and symptoms and that the three patients had the same mutation in the
gene encoding the enzyme, confirming the diagnosis.
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INTRODUCTION
Fabry disease is a rare storage metabolic disea-
se, linked to X chromosome, caused by deficiency of
α- galactosidase A (α-Gal A) lysosomal hydrolase acti-
vity, leading to the accumulation of two neutral gly-
cosphingolipids, globotriaosylceramide (GL-3 or Gb3)
and digalactosylceramide, in several tissues, with
progressive multisystemic damage.1-5
The angiokeratomas are part of the initial clini-
cal presentation, although asymptomatic.
Angiokeratomas, acroparestesias and non-specific
systemic symptoms are not initially associated with
Fabry disease, which postpones the beginning of
enzyme replacement therapy (ERT), increasing the
risk of late complications.6
We report three cases of Fabry disease in two
male brothers, in its classical form, as well as in the
oligosymptomatic mother.
CASES REPORT
Case 1: 16-year-old male, with asymptomatic
periumbilical lesions since his first years of life, pro-
gressing in number and size for the last 3 years. He
presented right hypoacusia, tingling in hands and feet
and burning plantar pain, which worsened with hot
weather and physical activity.
At the dermatological exam he presented eryt-
hematous-violaceous papules of keratotic surface,
grouped on the upper limbs, paravertebral, paraumbi-
lical, inguinal, scrotum and penile regions, right thigh
and knees (Figure 1). In the ophthalmological investi-
gation the diagnosis was cornea verticillata (Figure 2).
He presented hearing deficit in the right ear at audio-
metry. In complementary exams, he showed high 24-
hours proteinuria (0.14; VR < 0.05); remaining exams
were normal (blood count, renal function, microalbu-
minuria, ECG, spirometry and cranial magnetic reso-
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nance imaging-MRI). The deficiency of α-Gal activity
was confirmed in the plasma (0.0 umol/h of protein;
> 2.5) and leukocytes through paper filter (0.16 nmol
/ h / mg of protein; > 1.4). The biopy of umbilical
lesion resulted compatible with angiokeratoma
(Figure 3).
Case 2: an 11-year-old boy presented burning
pains in the lower limbs, which worsened with hot
weather, although less intensively than in his brot-
her’s case (Case 1). During examination angiokerato-
mas were noticed, limited to the periumbilical region.
He presented cornea verticillata, while the audiome-
try and other laboratory, electrocardiographic and
imaging exams were normal. Enzyme α- Gal A defi-
ciency was observed in the plasma and leukocytes
(plasma: 0.11 umol/h; leukocytes: 0.46 nmol/mg/h).
Case 3: a 39-year-old female, mother of patients
1 and 2, presented with mild acroparestesia and  cor-
nea verticillata, without skin lesions. Audiometry
revealed diminished hearing in the right ear and
slight loss in the left, discrete proteinuria (0.09) and
microalbuminuria (20.93 VR < 20 ). Normal blood
count, renal function, ESR, ECG and cranial MRI.
Dosage of α-Gal A activity in the plasma was within
normal range (3.02 umol/h).
Genotyping of the 3 patients revealed a similar
mutation: Exon 7 Arg 342 Gln. In the two-year follow-
up, patient 1 presented worsening of lower limb pains
and microangiopathy was detected in cranial MRI.
Patient 2 started presenting proteinuria and increase
of angiokeratomas in size, number and distribution.
The mother remained stable. The three patients still
have not started enzyme replacement due to family
decision of postponing the beginning of treatment.
DISCUSSION
Fabry disease was originally described in 1898
as ‘angiokeratoma corporis diffusum’ by Anderson and
Fabry.2,3 Later it was recognized as a systemic lysoso-
mal storage disease, caused by a mutation of α–Gal
gene A(Xq22.1), leading to alteration of enzyme
expression.1,2 This deficiency leads to accumulation of
neutral glycosphingolipids, particularly globotriao-
sylceramide (Gb3) and digalactosylceramide, mainly
in the central nervous system, skin, heart, kidneys,
auditory system and eyes.3,6
FIGURE 1: A. Keratotic erythematous-violaceous papules, distributed
on the umbilical and paraumbilical areas. B. Keratotic violaceous
papules distributed on scrotum and penile body
FIGURE 2: Cornea verticillata: Yellowish lines that converge to a spot
close to central cornea region
FIGURE 3:
A. Proliferation of capil-
lary vases, ectasia and
congestion of the lumen
in the papillary dermis,
thickening of epidermis
(HE100X). 
B. Proliferation of capil-
lary vases, ectasied,
congested close to the
dome of the papillary
dermis (HE 400X)A B
A B
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The clinical expression of the disease depends on
the α–galactosidase enzyme activity, whereas patients
with residual enzymatic activity show a milder clinical
picture, with predominance of cardiac alterations, pos-
sibly with minimal renal damage and absence of acro-
parestesia, which does not occur in the classical form of
the disease, when the enzymatic activity is absent.2,7
This can be explained by more than 400 different gene
mutations, some of them leading to some residual
enzymatic activity varying between 2 to 25%.2
Even though it is considered a recessive disease
linked to X chromosome, heterozygous women can
manifest the disease symptoms in 70 % of the cases,
due to random activation of chromosome X, not being
merely carriers of the mutation.2,3 This way, it is neces-
sary to investigate and follow up female patients of
families that carry Fabry disease, as was done with the
patients’ mother.
The classical form occurs in the male gender, as
presented in the two brothers. The initial symptoms
appeared in infancy, predominantly neurological, like
acroparestesias, generalized pains, change of thermal
sensitivity, hearing loss and hypohidrosis, but also
gastrointestinal, including abdominal pain and chan-
ge of intestinal habit.1,2,3,4 The cornea verticillata may
be present since early childhood.6 Angiokeratomas are
papules of red to purplish coloration, of varying sizes
and tending to grow in number and size with age.
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They are distributed mainly on the periumbilical and
inguinal areas, in swimsuit form.1,7 Angiokeratomas
and cornea verticillata, when present, are a clue to an
early diagnosis.7
The late manifestations occur in the third and
fourth decades; the main ones are: chronic renal disea-
se, cardiac arrhythmias and cerebral vascular acci-
dent, which contribute to reduce life expectancy of
patients by 15 to 20 years.7 Early diagnosis is impor-
tant for the establishment of enzymatic replacement
treatment, diminishing Gb3 deposits in the vascular
endothelium and plasma, with stabilization of renal
function in children and postponing disease progress
in adults.7,8,9 Recent studies suggest that, in spite of
variable ERT response among patient subgroups, the
treatment started before the occurrence of irreversible
damage to organs could prevent late complications,
with reduction of morbidity and mortality related to
the disease.5,10
We reported three cases of Fabry disease in
first-degree relatives. The index patient received the
diagnosis at 16 years of age, despite the presence of
angiokeratomas since early childhood, which
demonstrates the importance of dermatologists and
pediatricians knowing the condition to ensure that
early enzymatic treatment is ministered, capable of
avoiding late complications of the disease. q
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